Lung cancer study aims to predict dangerous lung inflammation

NCT ID NCT06192004

Terminated Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effect of cancer therapy. The study was observational, meaning no new treatment was given, and it was ended early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a digital tool that helps doctors identify lung cancer patients at risk of pneumonitis/ILD earlier.
What could go wrong: This study was terminated early with only 83 participants, so results may be limited. It is observational, not testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease non-small cell lung carcinoma pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Los Angeles, California, 90027, United States
Research Site

Los Angeles, California, 90033, United States
Research Site

Denver, Colorado, 80204, United States
Research Site

Golden, Colorado, 80222, United States
Research Site

Miami Lakes, Florida, 33014, United States
Research Site

Skokie, Illinois, 60076, United States
Research Site

Ames, Iowa, 50010-3014, United States
Research Site

Covington, Louisiana, 70433, United States
Research Site

Troy, Michigan, 48098, United States
Research Site

Florham Park, New Jersey, 07932, United States
Research Site

Mickleton, New Jersey, 08056, United States
Research Site

Shirley, New York, 11967, United States
Research Site

Westbury, New York, 11590, United States
Research Site

Canton, Ohio, 44708, United States
Research Site

Canton, Ohio, 44710, United States
Research Site

Cincinnati, Ohio, 45219, United States
Research Site

Massillon, Ohio, 44646, United States
Research Site

York, Pennsylvania, 17403, United States
Research Site

Austin, Texas, 78745, United States
Research Site

Dallas, Texas, 75246, United States
Research Site

Houston, Texas, 77024, United States
Research Site

Longview, Texas, 75601, United States
Research Site

Odessa, Texas, 79902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.